Odyssey Group International Approved to Start Human Trial to Treat Concussion        

IRVINE, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced its approval to begin Phase 1 human clinical trials for drug candidate PRV-002 intended to treat concussions. The...

Click to view original post